<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00425204</url>
  </required_header>
  <id_info>
    <org_study_id>20020375</org_study_id>
    <secondary_id>Abgenix Protocol No. ABX-0311</secondary_id>
    <nct_id>NCT00425204</nct_id>
    <nct_alias>NCT00081185</nct_alias>
  </id_info>
  <brief_title>Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment</brief_title>
  <official_title>A Multi-Center, Open-Label Clinical Trial To Determine The Safety of ABX-EGF As Continued Treatment For Patients Who Have Benefited From and Tolerated Prior ABX-EGF Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      A multi-center, open-label, extended treatment, clinical trial examining the safety of
      administering multiple does of panitumumab by intravenous (i.v.) infusion to patients who
      have previously received panitumumab and benefited from treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide continued, extended panitumumab treatment to subjects who appeared to have benefited from and tolerated previous panitumumab treatment in Studies 20020374 Part 2 or 20030138 and its extension study, 20040116</measure>
    <time_frame>Until disease progression, an AE or withdrawn consent</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety of multidose administration of panitumumab in subjects who received continued and extended panitumumab treatment</measure>
    <time_frame>Until disease progression, an AE or withdrawn consent</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Solid Tumors</condition>
  <condition>Advanced Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab (ABX-EGF)</intervention_name>
    <description>Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.</description>
    <arm_group_label>Open Label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to comprehend and sign an IRB approved Informed Consent Form

          -  Male or female 18 years of age or older

          -  Female patients who are post menopausal (no menstrual period for a minimum of six
             months), surgically sterilized, or are using an oral or implanted contraceptive,
             double barrier birth control, or an intrauterine device (IUD) and have a negative
             serum pregnancy test upon entry into this study; or male patients willing to use
             contraception upon enrollment and during the course of the study

          -  Previously received and tolerated panitumumab treatment on studies 20020374 Part 2 or
             20030138/20040116

          -  Is considered &quot;stable&quot; or &quot;responding&quot; based on the RECIST (20020374 Part 2) or WHO
             (20040116) criteria, at the final treatment visit of the previous panitumumab clinical
             trial and the screening visit for this study

          -  No more than 2 months (60 days) have elapsed since the final treatment visit of the
             previous panitumumab clinical trial

          -  Karnofsky score &gt; or = 70%

        Exclusion Criteria:

          -  Brain metastases (20040116 patients are allowed only if controlled and asymptomatic)

          -  Uncontrolled hypercalcemia (calcium level outside the upper limit of normal;
             antihypercalcemic treatment is allowed). Exception: Patients in the Motzer
             Intermediate Risk Group from 20020374 Cohort 2 with uncontrolled high corrected
             calcium (&gt;10 mg/dl) may be enrolled

          -  Use of any anti-tumor therapy or investigational drug, other than panitumumab, between
             the last visit of the previous panitumumab study and the initial visit in this
             20020375 study

          -  Prior treatment with another anti-EGFr agent, other than panitumumab

          -  Myocardial infarction within 1 year prior to entering the study

          -  Has other cancer that has been active and required treatment within the past 5 years
             (basal cell carcinoma or cervical carcinoma in situ are allowed)

          -  Pregnant or breast feeding female; female of childbearing potential (defined as: post
             menarche and is biologically capable of becoming pregnant) unwilling to use birth
             control (as defined in the inclusion criteria) during and for 6 months following
             treatment

          -  Male patient unwilling to use birth control (as defined in the inclusion criteria)
             during and for 1 month following treatment

          -  Known to be HIV positive

          -  History of any chronic medical or psychiatric condition or laboratory abnormality that
             in the opinion of the Investigator may increase the risks associated with study drug
             administration

          -  Allergy to the ingredients of the study medication or to Staphylococcus Protein A

          -  History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial
             pneumonitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.vectibix.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2007</study_first_submitted>
  <study_first_submitted_qc>January 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2007</study_first_posted>
  <last_update_submitted>September 11, 2008</last_update_submitted>
  <last_update_submitted_qc>September 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

